| Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer F Innocenti, RL Schilsky, J Ramírez, L Janisch, S Undevia, LK House, ... Journal of clinical oncology 32 (22), 2328-2334, 2014 | 155 | 2014 |
| Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases Y Liu, J Ramírez, L House, MJ Ratain Drug Metabolism and Disposition 38 (1), 32-39, 2010 | 117 | 2010 |
| Personalized targeted therapy for lung cancer K Wu, L House, W Liu, WCS Cho International Journal of Molecular Sciences 13 (9), 11471-11496, 2012 | 89 | 2012 |
| Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients EEW Cohen, K Wu, C Hartford, M Kocherginsky, KN Eaton, Y Zha, ... Clinical Cancer Research 18 (17), 4785-4793, 2012 | 81 | 2012 |
| A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R (+) XK469 in patients with advanced solid tumours SD Undevia, F Innocenti, J Ramirez, L House, AA Desai, LA Skoog, ... European journal of cancer 44 (12), 1684-1692, 2008 | 77 | 2008 |
| Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies TC Gangadhar, EEW Cohen, K Wu, L Janisch, D Geary, M Kocherginsky, ... Clinical Cancer Research 17 (7), 1956-1963, 2011 | 45 | 2011 |
| Next-generation sequencing for lung cancer K Wu, RS Huang, L House, WC Cho Future Oncology 9 (9), 1323-1336, 2013 | 43 | 2013 |
| A pharmacogenetic study of vorinostat glucuronidation SP Kang, J Ramirez, L House, W Zhang, S Mirkov, W Liu, E Haverfield, ... Pharmacogenetics and genomics 20 (10), 638-641, 2010 | 39 | 2010 |
| Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancer K Wu, EEW Cohen, LK House, J Ramírez, W Zhang, MJ Ratain, RR Bies CPT: pharmacometrics & systems pharmacology 1 (12), 1-6, 2012 | 35 | 2012 |
| Simultaneous determination of 5-fluorouracil and uracil by high-performance liquid chromatography using four serial columns LK House, J Ramı́rez, MJ Ratain Journal of Chromatography B: Biomedical Sciences and Applications 720 (1-2 …, 1998 | 28 | 1998 |
| The UGT1A1∗ 28 polymorphism correlates with erlotinib’s effect on SN-38 glucuronidation Y Liu, J Ramírez, L House, MJ Ratain European Journal of Cancer 46 (11), 2097-2103, 2010 | 27 | 2010 |
| A phase I study of sirolimus and bevacizumab in patients with advanced malignancies EEW Cohen, MR Sharma, L Janisch, M Llobrera, L House, K Wu, ... European Journal of Cancer 47 (10), 1484-1489, 2011 | 24 | 2011 |
| Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer WP Yong, AA Desai, F Innocenti, J Ramirez, D Shepard, K Kobayashi, ... Cancer chemotherapy and pharmacology 60, 811-819, 2007 | 24 | 2007 |
| Glucuronidation of OTS167 in humans is catalyzed by UDP-glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10 J Ramírez, S Mirkov, LK House, MJ Ratain Drug metabolism and disposition 43 (7), 928-935, 2015 | 16 | 2015 |
| Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies S Karovic, Y Wen, TG Karrison, GL Bakris, MR Levine, LK House, K Wu, ... Clinical Pharmacology & Therapeutics 96 (1), 27-35, 2014 | 16 | 2014 |
| Clinically actionable genotypes for anticancer prescribing among> 1500 patients with pharmacogenomic testing NM Reizine, K Danahey, TM Truong, D George, LK House, TG Karrison, ... Cancer 128 (8), 1649-1657, 2022 | 9 | 2022 |
| Prolonged pharmacokinetic interaction between capecitabine and a CYP2C9 substrate, celecoxib J Ramírez, LK House, TG Karrison, LA Janisch, M Turcich, R Salgia, ... The journal of clinical pharmacology 59 (12), 1632-1640, 2019 | 9 | 2019 |
| In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7 L House, J Ramirez, M Seminerio, S Mirkov, MJ Ratain Xenobiotica 45 (11), 990-998, 2015 | 9 | 2015 |
| Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs K Wu, L House, J Ramírez, MJ Seminerio, MJ Ratain Clinical Cancer Research 19 (21), 6039-6043, 2013 | 9 | 2013 |
| A genotype-directed phase I study of irinotecan in advanced cancer patients F Innocenti, L Janisch, S Das, J Ramirez, L House, ML Maitland, R Salgia, ... Journal of Clinical Oncology 25 (18_suppl), 2502-2502, 2007 | 9 | 2007 |
